Mastek Q2 FY27 presentation: revenue tops ₹1,000 cr as AI shift accelerates

Mastek reported Q2 FY27 revenue of ₹1,018.7 crore, up 2.4% sequentially in constant currency, while operating EBITDA margin contracted 109 bps sequentially to 14.4% and its 12-month order backlog fell 7.7% to $286.2 million. Shares declined 6.76% to $1,642.5 after the results. AI momentum was a positive, with 53 AI-related deals versus 43 in the prior quarter and an AI order book of $41.3 million; management maintained its FY27 outperformance outlook and targets at least 160 bps year-over-year margin improvement.

Analysis

The investable signal is not the revenue milestone or AI-deal count; it is whether delivery economics improve as the work mix shifts. Fixed-price contracts and AI-heavy engagements can lift margins if automation reduces labor hours per outcome, but they also concentrate execution risk with Mastek: utilization is down and the reported margin pressure suggests productivity gains have not yet offset wage, ESOP and mix costs. Deal counts are not contract value, and management’s pipeline claims need conversion evidence.

Near term (days to weeks), the backlog decline and margin miss leave the shares vulnerable to further estimate caution; the post-results selloff alone is not a valuation signal. Over 1–3 months, watch backlog stabilization, utilization, and whether the delayed North American and UK healthcare work converts into revenue. Over 6–18 months, localization and security-cleared staffing requirements could structurally raise UK delivery costs even if public-sector demand improves. A recovery toward the stated margin ambition would require measurable year-over-year expansion, not just AI positioning.

The contrarian angle is that the market may be discounting the AI opportunity too quickly, but the evidence is currently leading indicators rather than realized economics. Conversely, AI-led SaaS rationalization is a possible longer-term headwind for Salesforce and Oracle, both referenced in client work, but this quarter does not establish material license substitution or financial exposure for either company.

Key Decisions for Investors

• No direct trade in CRM or ORCL: Mastek’s engagements involving Salesforce and Oracle do not establish material revenue or earnings sensitivity for either vendor. Treat SaaS-seat rationalization as a watch item, not a short thesis, pending client adoption and vendor-disclosed evidence.
• For Mastek, avoid chasing the post-results decline; consider reassessing after the next operating update. The confirmation checklist is sequential backlog stabilization, utilization recovery, and year-over-year EBITDA-margin improvement. Failure on those measures would weaken the AI-productivity thesis.
• Track the next 1–3 months for conversion of delayed North American deals and UK healthcare contracts. If backlog continues to contract or revenue conversion slips, the downside risk is that AI deal momentum fails to replace slower legacy work; if conversion and margins improve together, the selloff may prove overdone.
• Verify the exact listed security, reported share-price currency, and valuation before sizing any Mastek position; the article’s price presentation is not sufficient for a price-level-based trade.